Rochester Network Lead Academic Participating Site

项目总结/摘要 罗切斯特大学威尔莫特癌症研究所是一个健康和研究机构，非常适合实现 NCI NCTN作为领先学术网站的目标。我们作为U10资助成员的长期活动 ECOG（1968-2002）和SWOG（2002-2012）以及我们过去5年对NCTN试验的贡献 表明我们对癌症临床和转化实验室研究持续投资和承诺， 特别是晚期癌症临床试验的开发和积累。在一个生物学和生物学都 癌症和新的治疗策略的发展变得更加复杂，需要 多学科的研究团队和广泛的组织库和相关研究，我们的翻译 科学的计划和对NCTN计划的奉献是最终成功的关键。 我们的临床试验计划由一个领导小组和跨医学系的教师组成 （血液学和内科肿瘤学）、外科、泌尿科、放射肿瘤学和妇产科， 在NCTN项目上投入了大量资金NCTN试验结构是我们临床试验的关键组成部分 办公室，并利用多学科疾病工作组作为方案管理中心，确保 适当和广泛的专业知识。我们在NCTN团体中的领导角色，委员会成员， 出版记录和科学成就使我们能够继续为最终的 NCTN的使命。我们在协调合作小组研究方面有着悠久的历史，并将继续这样做， 在罗切斯特大学进行的初步工作的基础上， 基于NCTN组。 在2014年至2017年期间，我们能够快速启动NCTN临床试验，累积了100多名患者 平均每年提交一次，并以有效的方式提交高质量的数据。因此，罗切斯特被 被NCI评为高性能站点。我们计划在整个网络中进一步加强这方面的努力， 扩大区域存在，同时继续关注代表性不足的患者群体，包括 肥胖/年轻成人和老年人群。我们已经带领国家进行了几项重要的研究， 包括对罕见疾病进行的研究，以及我们为提高少数族裔应计费用所做的努力， 代表我们总体人群的临床试验的累积。罗切斯特大学致力于 该委员会将继续执行国家技术和贸易网络的使命，并将继续为在国家技术和贸易网络开展和开展相关试验作出贡献。 最高水平。

PROJECT SUMMARY/ABSTRACT The University of Rochester, Wilmot Cancer Institute is a health and research institute ideally suited to achieve the goals of the NCI NCTN as a Lead Academic Site. Our longstanding activity as U10-funded members of ECOG (1968-2002) and SWOG (2002-2012) as well as our dedication to NCTN trials over the past 5 years indicate our continued investment in and commitment to clinical and translational laboratory research in cancer, particularly the development of and accrual to late-phase Cancer Clinical Trials. In an era where both the biology of cancer and development of novel therapeutic strategies have become more complex, requiring multidisciplinary teams of investigators and extensive tissue banking and correlative studies, our translational scientific program and dedication to the NCTN program is critical for ultimate success. Our Clinical Trials Program consists of a leadership group and faculty across the departments of medicine (hematology and medical oncology), surgery, urology, radiation oncology and obstetrics and gynecology who are highly invested in the NCTN program. The NCTN trials structure is a key component of our Clinical Trials Office, and utilizes multidisciplinary disease Working Groups as the hub for protocol management, ensuring appropriate and broad-based expertise. Our leadership roles within the NCTN groups, committee membership, publication record, and scientific achievements position us well for continued quality contributions to the ultimate mission of NCTN. We have a long history of coordinating cooperative group studies and continue to do so, building on preliminary work conducted at University of Rochester but also collaborating across all of the US based NCTN groups. Between 2014 and 2017, we were able to activate NCTN clincal trials quickly, accrued more than 100 patients annually on average, and submitted high quality data in an efficient manner. As such, Rochester was recogized as a High Performing Site by the NCI. We plan to further increase this effort across the Network given our expanded regional presence, while continuing to focus on underrepresented patient groups including the adolesent/young adult and geriatric populations. We have led the country in accrual to several important studies, including studies conducted on rare diseases, and our efforts to enhance minority accrual have resulted in accrual to clinical trials representative of our overall population. The University of Rochester is dedicated to the mission of the NCTN and will continue to contibute to the development and conduct of associated trials at the highest level.